WuXi AppTec, UK Ltd

Syneos Health UK Limited

UK ends uncertainty over CE marking for medical devices

Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government has decided to recognise CE markin...

GSK to cut 1,200 jobs in Belgium

More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.

Novo raises outlook amid Wegovy pill succes

Novo's obesity drugs keeps driving sales, and the launch of the Wegovy pill makes Novo raise its full-year outlook.

Study finds key gut bacterium undetectable in one in three Swedish infants

One in three Swedish infants have no detectable levels of a bacterium that helps support the developing immune system, according to a new Swedish study. The fig...

Saniona’s neurology collaboration advances as AstronauTx Exercises acquisition option

UK‑based AstronauTx exercises an option to acquire a drug program in neurological diseases from Danish‑Swedish Saniona.

Camurus takes next step with Oczyesa – wins Canadian approval

Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients c...

AstraZeneca opens $1bn R&D centre in US

AstraZeneca has now opened its new research and development centre in Cambridge, Massachusetts – an investment of nearly 1 billion dollars.

Natural Cycles sharpens Nordic focus with new regional chief

After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.

Tandem Health raises $100m to expand in Europe

Swedish AI company Tandem Health has raised $100m. The funding will be used to strengthen the company’s position in Europe.

How GLP-1 drugs are changing what we buy at the supermarket

In both Sweden and Denmark, grocery industry organisations are predicting billion-krona sales losses as the use of weight-loss drugs increases. So far, however,...

Sweden takes half of Nordic spots among world’s top healthtech companies

Ten Nordic companies have made it onto TIME’s list of the World’s Top HealthTech Companies 2026, and half of them are Swedish. Denmark accounts for three, while...

Danish BioInnovation Institute sets sights on Europe

Great science is not enough to build successful companies. As BioInnovation Institute looks beyond Denmark, CEO Jens Nielsen sees access to the right capital as...

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

GSK’s potential blockbuster makes Swedish comeback

Following the withdrawal of its marketing authorisation and an earlier recommendation against its use, GSK’s Blenrep is making a comeback in Sweden. The Swedish...

Massläcka från känd biobank – data från halv miljon ute till försäljning

Medicinska uppgifter från omkring 500 000 britter har lagts ut till försäljning på en kinesisk e-handelsplattform. Datan kommer från forskningsdatabasen UK Biob...

Sanofi Sweden: ”We will work for more clinical trials”

Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact...

BioArctic chair: “First, you need to know where you’re going”

He has been a researcher, doctor, investor and business leader. But when Eugen Steiner explains BioArctic’s success, he keeps coming back to the same thing: its...

Multicancer test failed to meet its goal – shares plunged

A blood test designed to detect multiple types of cancer failed to meet its primary endpoint in a large UK study. The company behind the test saw its market value cut in half.

Hansa Biopharma secures billion deal: “Profitability within reach”

Lund-based Hansa Biopharma is raising more than SEK 1bn through a new licensing agreement for its in-house developed transplant drug imlifidase.

AstraZeneca´s Trixeo approved in the UK using propellant with near-zero Global Warming Potential

AstraZeneca has received approval in the United Kingdom for its inhaled respiratory medicine Trixeo Aerosphere with a new propellant that is reported to reduce ...

List: The companies behind 38 new pharmaceutical substances in the EU

In 2025, the European Medicines Agency (EMA) recommended 104 medicines for approval. Of these, 38 contained a new active substance that had never before been au...

Babypuderskandalen når Europa – första stämningen mot J&J i Storbritannien

De enorma skadeståndsprocesserna mot Johnson & Johnson, vars talkpuder påstås ha orsakat cancer, har nu även nått Storbritannien.